Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

What happened to the need to end commuting and presenteeism? Or to our gratitude for healthcare workers or our resolution to ...

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.

Business Facilities magazine has chosen the Delaware Prosperity Partnership-led effort to help Incyte retain and expand ...

Moderna will outline its fourth-quarter results on Feb. 14, offering a more detailed financial picture and updates on its cost-cutting measures. The company plans to focus on late-stage trials for ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

Moderna's share price plunged after the company cut its 2025 sales guidance. The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product ...